Nifty Pharma witness modest gains; Lupin top bull; Divi's Lab, Cadila worst hit

Nifty Pharma trades bullish with 7 scrips were in advancing note.

September 29, 2021 10:45 IST | India Infoline News Service
The Nifty Pharma index was on the upsurge despite bearish tone amid weak global cues on Wednesday. The index witnessed buying sentiments led by a bullish run on major stocks like Lupin, Dr Reddys and Sun Pharma. However, the steep selloff in Divis Lab and Cadila stocks led the index to pull back slightly.

During early trading deals, at around 10:45 AM, Nifty Pharma performs at 14,239.30 up by 67.70 points or 0.48%. The index has touched an intraday high of 14,343.35 and intraday low of 14,172.50 during early trading session on Wednesday.

Markets were under pressure today as Sensex was down 540.31 points or 0.91% at 59,127.29, and the Nifty was down 106.65 points or 0.60% at 17,641.95.

On the trading window, Nifty Pharma trades bullish with 7 scrips were in advancing note.

Lupin performed as top bull surging by 2.63% at Rs950.60per piece followed by Dr Reddys and Sun Pharma gaining more than 1.5% each. 

Aurobindo Pharma and Biocon were on the upside by soaring around 1% each while Torrent Pharma and Cipla were marginally higher to lift the index.

However, heavyweight Divis Lab dragged the index by 5.57% at Rs4,823.85 per piece being the biggest laggard on the index along with Cadila Healthcare was down 3.40% at Rs544.90 per piece. Alkem Laboratories also shed more than 1%.

In the closing session of 4th Indo-US Health Dialogue being hosted by India, India and USA signed MoU for cooperation in Health and Biomedical Sciences. Further, MoU also signed between Indian Council of Medical Research (ICMR) & NIAID (NIH) for cooperation on International Centre for Excellence in Research (ICER).

OPEN A DEMAT ACCOUNT & Get FREE Benefits worth 10,000

FREE Benefits worth 10,000



The average score for Prestige Estates Projects Limited stands at 4 against 6, three months back.

Prestige Estates Projects Limited is engaged in the business of real estate development. The Company’s principal products/services include Development and construction



Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity